vascular dementia Stroke G30.0 G30.1 G30.8 G30.9 G20 G21 G22 G31.82 G23.1 G11.1 G11.0 G11.2 G11.3 G11.4 G11.8 G11.9 G12.2 I68.0
Conditions
Interventions
Group 1: Registration of clinical features, process, genetics and pathophysiology of neurodegenerative diseases and cerebro-vascular originated diseases.
Documentation of progress through annual visit
Sponsors
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - informed consent - diagnosis of a neurodegenerative disorder or a cerebro-vascular disease -Age > 18 -Willingness to undergo MRI scan(s) and/or lumbar puncture(s -Consent of the legal representative and Co-Consent for incapacitated subjects
Exclusion criteria
Exclusion criteria: - clinically unstable or serious diseases - existing or past passed mental, psychiatric or physical illness that by the opinion of the study physician precludes participation in the study --------------------------------------------------- --------------- exclusion criteria for the optional MRI scan: - electrical implants such as pacemakers or perfusion pumps - pregnancy and pronounced claustrophobia - concomitant medications that have a strong sedating effect - presence of ferromagnetic or electrically conductive implants such as aneurysm clips, surgical clips, prostheses, artificial hearts, flaps with metal parts, metal pieces, large tattoos, permanent makeup or steel implants
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of this study is to establish a clinical register to represent clinic, history, genetics and pathophysiology of neurodegenerative diseases (Alzheimer Disease, fronto-temporal dementia, Parkinson disease, progressive supranuclear palsy, amyotrophic lateral sclerosis, ataxias) and cerebro-vascular originated diseases (after stroke amyloid angiopathy). In the long term the development of neurodegenerative diseases are better understood through the analysis of data and the possibilities of early and differential diagnosis can be improved. Annual follow-up visits are pursued. | — |
Secondary
| Measure | Time frame |
|---|---|
| Another aim of the DESCRIBE Register trial is quickly well-characterized participants to contact for participating in other studies, where the people have agreed to this approach. | — |
Countries
Germany
Contacts
Public Contactc/o Klinische Forschungsplattform
Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE)
Outcome results
None listed